Free Trial

Integra LifeSciences (IART) Stock Price, News & Analysis

Integra LifeSciences logo
$14.00 +0.78 (+5.90%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$13.00 -1.01 (-7.18%)
As of 05/6/2026 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Integra LifeSciences Stock (NASDAQ:IART)

Advanced

Key Stats

Today's Range
$13.20
$14.12
50-Day Range
$8.90
$14.00
52-Week Range
$8.70
$16.49
Volume
2.30 million shs
Average Volume
928,494 shs
Market Capitalization
$1.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.20
Consensus Rating
Reduce

Company Overview

Integra LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

IART MarketRank™: 

Integra LifeSciences scored higher than 26% of companies evaluated by MarketBeat, and ranked 704th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and 3 sell ratings.

  • Upside/Downside

    The consensus price target for Integra LifeSciences is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Integra LifeSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Integra LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Integra LifeSciences are expected to grow by 3.67% in the coming year, from $2.45 to $2.54 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Integra LifeSciences is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Integra LifeSciences is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Integra LifeSciences has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.18% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 12.05, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently increased by 3.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Integra LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Integra LifeSciences does not have a long track record of dividend growth.

  • News Sentiment

    Integra LifeSciences has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Integra LifeSciences this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for IART on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Integra LifeSciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.84% of the stock of Integra LifeSciences is held by insiders.

  • Percentage Held by Institutions

    84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Integra LifeSciences' insider trading history.
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IART Stock News Headlines

Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
Integra LifeSciences Announces Leadership Transition
See More Headlines

IART Stock Analysis - Frequently Asked Questions

Integra LifeSciences' stock was trading at $12.42 on January 1st, 2026. Since then, IART shares have increased by 12.7% and is now trading at $14.00.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) released its quarterly earnings data on Tuesday, May, 5th. The life sciences company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. The company's quarterly revenue was up 2.4% compared to the same quarter last year.
Read the conference call transcript
.

Integra LifeSciences's stock split before market open on Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences subsidiaries include these companies: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and more.

Integra LifeSciences' top institutional shareholders include Bank of New York Mellon Corp (0.61%), Assenagon Asset Management S.A. (0.54%), Leeward Investments LLC MA (0.46%) and Principal Financial Group Inc. (0.42%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen, Jeffrey A Graves and Witte Jan De.
View institutional ownership trends
.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

Last Earnings
5/05/2026
Today
5/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IART
CIK
917520
Employees
4,427
Year Founded
1989

Price Target and Rating

High Price Target
$25.00
Low Price Target
$11.00
Potential Upside/Downside
+8.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
5.71
P/E Growth
N/A
Net Income
-$516.47 million
Net Margins
-30.15%
Pretax Margin
-32.59%
Return on Equity
17.43%
Return on Assets
4.98%

Debt

Debt-to-Equity Ratio
1.66
Current Ratio
2.54
Quick Ratio
1.46

Sales & Book Value

Annual Sales
$1.64 billion
Price / Sales
0.67
Cash Flow
$4.47 per share
Price / Cash Flow
3.13
Book Value
$13.40 per share
Price / Book
1.04

Miscellaneous

Outstanding Shares
77,940,000
Free Float
74,944,000
Market Cap
$1.09 billion
Optionable
Optionable
Beta
1.08

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:IART) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners